Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats

Area of Science:

• Endocrinology
• Urology
• Pharmacology

Background:

• Diabetic mellitus (DM) commonly leads to erectile dysfunction (ED), a challenging complication.
• Poly(ADP-ribose) polymerase (PARP) activation is implicated in the neurovascular dysfunction underlying diabetic ED.

Purpose of the Study:

• To evaluate the potential preventive effects of a PARP inhibitor on diabetes-induced ED.
• To investigate the mechanism of action of PARP inhibition in a rat model of diabetic ED.

Main Methods:

• Streptozotocin-induced diabetic rats were treated with PJ-34, a selective PARP inhibitor.
• Erectile function, PARP activity, reactive oxygen species (ROS), nitric oxide synthase (NOS) isoforms, nuclear factor-kappa B (NF-κB) activation, and apoptosis were assessed.

Main Results:

• PJ-34 treatment partially restored erectile function in diabetic rats.
• PARP inhibition by PJ-34 reduced oxidative stress, blocked PARP activity, and normalized NOS expression and activity.
• PJ-34 also mitigated diabetes-induced apoptosis and NF-κB activation in the corpus cavernosum.

Conclusions:

• PARP activation is a key factor in the development of diabetic ED.
• PARP inhibition presents a potential therapeutic strategy for preventing diabetic ED.